Pharmacoresistant epilepsy: Definition and explanation

Epileptology

Volumn 1, Issue 1, 2013, Pages 38-42

  Alexopoulos, Andreas V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anticonvulsants; Drug resistance; Epilepsy drug therapy; Epilepsy surgery; Treatment failure

Indexed keywords

ANTICONVULSIVE AGENT; BIOLOGICAL MARKER; MULTIDRUG RESISTANCE PROTEIN; VOLTAGE GATED SODIUM CHANNEL BETA 1 SUBUNIT;

ARTICLE; AUTOIMMUNITY; COST OF ILLNESS; DIAGNOSTIC ERROR; DISEASE SEVERITY; DRUG EFFICACY; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENVIRONMENTAL EXPOSURE; EPILEPSY; GENE MUTATION; GENETIC POLYMORPHISM; HEALTH CARE COST; HUMAN; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHARMACORESISTANT EPILEPSY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGNOSIS; SCN1B GENE; SUDDEN DEATH; THERAPEUTIC ERROR;

EID: 84878358742     PISSN: 22128220     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.epilep.2013.01.001     Document Type: Article

References (50)

1. Alexopoulos AV, Gonugunta V, Yang J, Boulis NM. Electrical stimulation and gene-based neuromodulation for control of medically-refractory epilepsy. Acta Neurochir Suppl 2007; (97) 2007; Pt 2:293-309.
2. Beck H., Yaari Y. Antiepileptogenesis, Plasticity of AED targets, drug resistance, and targeting the immature brain. Jasper's Basic Mechanisms of the Epilepsies 2012, National Center for Biotechnology Information (US), Bethesda, MD. 4th ed. J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
3. Berg A.T. Understanding the delay before epilepsy surgery: who develops intractable focal epilepsy and when?. CNS Spectrum 2004, 9(2):136-144.
4. Berg A.T., Shinnar S., Levy S.R., Testa F.M., Smith-Rapaport S., Beckerman B. Early development of intractable epilepsy in children: a prospective study. Neurology 2001, 56(11):1445-1452.
5. Berg A.T., Langfitt J., Shinnar S., Vickrey B.G., Sperling M.R., Walczak T., et al. How long does it take for partial epilepsy to become intractable?. Neurology 2003, 60(2):186-190.
6. Berg A.T., Vickrey B.G., Testa F.M., Levy S.R., Shinnar S., DiMario F., et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 2006, 60(1):73-79.
7. Callaghan B.C., Anand K., Hesdorffer D., Hauser W.A., French J.A. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007, 62(4):382-389.
8. Callaghan B., Schlesinger M., Rodemer W., Pollard J., Hesdorffer D., Allen Hauser W., et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 2011, 52(3):619-626.
9. Chapell R., Reston J., Snyder D., Treadwell J., Treager S., Turkelson C. Management of treatment-resistant epilepsy. Evid Rep Technol Assess (Summ) 2003, 77:1-8.
10. Dudek F.E., Bertram E.H., Staley K.J. Antiepileptogenesis Therapy with Levetiracetam: Data from Kindling versus Status Epilepticus Models. Epilepsy Curr 2008, 8(1):28-30.
11. Faught E. Treatment of refractory primary generalized epilepsy. Rev Neurol Dis 2004, 1(Suppl 1):S34-S43.
12. Fountain NB, Van Ness PC, Swain-Eng R, Tonn S., Bever Jr CT. Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology; Jan 4 2011;76(1):94-9.
13. Gorter J.A., Potschka H. Drug resistance. Jasper's Basic Mechanisms of the Epilepsies 2012, National Center for Biotechnology Information (US), Bethesda, MD. 4th ed. J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
14. Granata T., Marchi N., Carlton E., Ghosh C., Gonzalez-Martinez J., Alexopoulos A.V., et al. Management of the patient with medically refractory epilepsy. Expert Rev Neurother 2009, 9(12):1791-1802.
15. Hamer H.M., Spottke A., Aletsee C., Knake S., Reis J., Strzelczyk A., et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006, 47(12):2165-2172.
16. Hitiris N., Mohanraj R., Norrie J., Sills G.J., Brodie M.J. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007, 75(2-3):192-196.
17. Jacoby A., Buck D., Baker G., McNamee P., Graham-Jones S., Chadwick D. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia 1998, 39(7):776-786.
18. Ko T.S., Holmes G.L. EEG and clinical predictors of medically intractable childhood epilepsy. Clin Neurophysiol 1999, 110(7):1245-1251.
19. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342(5):314-319.
20. Kwan P., Brodie M.J. Refractory epilepsy: a progressive, intractable but preventable condition?. Seizure 2002, 11(2):77-84.
21. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51(6):1069-1077.
22. Kwan P., Schachter S.C., Brodie M.J. Drug-resistant epilepsy. N Engl J Med. 8 2011, 365(10):919-926.
23. Langan Y., Nashef L., Sander J.W. Case-control study of SUDEP. Neurology 2005, 64(7):1131-1133.
24. Lhatoo S.D., Sander J.W. Cause-specific mortality in epilepsy. Epilepsia 2005, 46(Suppl 11):36-39.
25. Löscher W., Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 2010, 62(4):668-700.
26. Löscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005, 6(8):591-602.
27. Löscher W., Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006, 47(8):1253-1284.
28. Löscher W., Schmidt D. Mechanisms of tolerance and drug resistance. The Treatment of Epilepsy 2009, Wiley-Blackwell, Oxford, UK, p. 156-165. 3rd ed. S. Shorvon, E. Perucca, J. Engel (Eds.).
29. Lucas P.T., Meadows L.S., Nicholls J., Ragsdale D.S. An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res 2005, 64(3):77-84.
30. Marchi N., Hallene K.L., Kight K.M., Cucullo L., Moddel G., Bingaman W., et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2004, 2:37.
31. Marchi N., Granata T., Alexopoulos A., Janigro D. The blood-brain barrier hypothesis in drug resistant epilepsy. Brain 2012, 135(Pt 4):e211.
32. Marín-Padilla M. Perinatal brain damage, cortical reorganization (acquired cortical dysplasias), and epilepsy. Adv Neurol 2000, 84:153-172.
33. Mohanraj R., Brodie M.J. Determining pharmacological intractability. Epilepsy surgery: principles and controversies 2006, Taylor & Francis, New York, p. 3-19.
34. Mohanraj R., Brodie M.J. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006, 13(3):277-282.
35. Murray M.I., Halpern M.T., Leppik I.E. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996, 23(2):139-148.
36. Pati S., Alexopoulos A.V. Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies. Cleve Clin J Med 2010, 77(7):457-467.
37. Platt M., Sperling M.R. A comparison of surgical and medical costs for refractory epilepsy. Epilepsia 2002, 43(Suppl 4):25-31.
38. Potschka H. Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics 2010, 11(10):1427-1438.
39. Regesta G., Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999, 34(2-3):109-122.
40. Remy S., Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006, 129(Pt 1):18-35.
41. Rogawski M.A., Johnson M.R. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 2008, 8(5):127-130.
42. Semah F. The definition of intractability is a function of epilepsy syndrome. Epilepsy surgery: principles and controversies 2006, Taylor & Francis, New York, p. 20-25.
43. Semah F., Picot M.C., Adam C., Broglin D., Arzimanoglou A., Bazin B., et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence?. Neurology 1998, 51(5):1256-1262.
44. Siddiqui A., Kerb R., Weale M.E., Brinkmann U., Smith A., Goldstein D.B., et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003, 348(15):1442-1448.
45. Sillanpaa M. Remission of seizures and predictors of intractability in long-term follow-up. Epilepsia 1993, 34(5):930-936.
46. Sillanpaa M., Jalava M., Kaleva O., Shinnar S. Long-term prognosis of seizures with onset in childhood. N Engl J Med 1998, 338(24):1715-1722.
47. Smith D., Defalla B.A., Chadwick D.W. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. Q J Med 1999, 92(1):15-23.
48. Sperling M.R., Feldman H., Kinman J., Liporace J.D., O'Connor M.J. Seizure control and mortality in epilepsy. Ann Neurol 1999, 46(1):45-50.
49. Steffenburg U., Hedstrom A., Lindroth A., Wiklund L.M., Hagberg G., Kyllerman M. Intractable epilepsy in a population-based series of mentally retarded children. Epilepsia 1998, 39(7):767-775.
50. Tomson T., Nashef L., Ryvlin P. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol 2008, 7(11):1021-1031.